Thu.Feb 29, 2024

article thumbnail

STAT+: Change Healthcare cyber attack outage could persist for weeks, UnitedHealth Group executive suggests

STAT

The outage caused by the Change Healthcare cyberattack could last weeks, a top UnitedHealth executive suggested in a Tuesday conference call with hospital cybersecurity officers, according to a recording obtained by STAT. UnitedHealth Group Chief Operating Officer Dirk McMahon said the company is setting up a loan program to help providers who can’t submit insurance claims while Change is offline.

Hospitals 363
article thumbnail

Unlocking the Perfect Fit: Your Ultimate Guide to Selecting the Ideal Pharmacy School

Pharmacy Is Right For Me

Selecting the ideal pharmacy school involves weighing numerous factors, as no single institution suits everyone. By prioritizing your preferences, you can effectively streamline your list of prospective schools. You may ask yourself, “What are the factors I should consider when choosing a pharmacy school program?” Well, the answer to that will be different for each person.

Hospitals 246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

RSV vaccines may be linked to small increased risk of developing Guillain-Barré syndrome, data suggest

STAT

The new vaccines that protect older adults against respiratory syncytial virus, or RSV, may be linked to a small increased risk of developing Guillain-Barré syndrome, new data from the Centers for Disease Control and Prevention and the Food and Drug Administration suggest. At a meeting Thursday of the Advisory Committee on Immunization Practices, vaccine safety experts from the two agencies presented data that showed what appears to be an elevated rate of GBS, as the condition is called, am

Vaccines 359
article thumbnail

Biogen partner NeuroSense seeks a role in the ALS revolution

PharmaVoice

Results from a mid-stage study for a new ALS drug have been strong, and NeuroSense is looking to join a small but sturdy wave of companies bringing new treatments to market.

196
196
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

STAT+: Icon acquires HumanFirst to boost support for digital tools in clinical trials

STAT

As pharma companies wrestle with how and when to use wearables and other digital technologies to measure how their experimental drugs impact patients, clinical research giant Icon has acquired HumanFirst, which helps companies answer exactly those sorts of questions. Founded in 2017, HumanFirst maintains a meticulously organized library of digital measurement tools, their underlying evidence, and information about how they have been used in clinical trials.

article thumbnail

India’s Tata Institute develops tablet for cancer recurrence prevention

Pharmaceutical Technology

India’s Tata Institute has developed a tablet combining resveratrol and copper that has the potential to prevent the recurrence of cancer.

143
143

More Trending

article thumbnail

FDA, Industry Actions End Sales of PFAS Used in US Food Packaging

LifeProNow

February 28, 2024: “The U.S. Food and Drug Administration is announcing that grease-proofing materials containing per- and polyfluoroalkyl substances (PFAS) are no longer being sold for use in food packaging in the U.S. This means the major source of dietary exposure to PFAS from food packaging like fast-food wrappers, microwave popcorn bags, take-out paperboard containers and pet food bags is being eliminated.

Packaging 100
article thumbnail

STAT+: A ‘vaccine-like’ version of Wegovy is on the drawing board at Novo Nordisk

STAT

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine? That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

Vaccines 361
article thumbnail

Scaling innovation across hospitals and nations

pharmaphorum

Explore how innovation in healthcare can be scaled across hospitals and nations, driving transformation through research & development, biotech collaborations, and fostering start-ups in the industry.

Hospitals 122
article thumbnail

STAT+: Here are the cancer drugs Pfizer thinks could reignite investors’ interest

STAT

Pfizer spent more than four hours Thursday laying out its oncology program to investors. But the company also spent some time talking about the effects of the Inflation Reduction Act on its pipeline. The drug giant, which is facing investor dissatisfaction after a year in which its stock dropped 44%, said it would be focusing on drugs that are based on proteins, not small molecule pills as it has traditionally developed.

article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

What Your Pharmacy Can Do for National Nutrition Month

Digital Pharmacist

Did you know March is National Nutrition Month ? National Nutrition Month is an annual campaign sponsored by the Academy of Nutrition and Dietetics and it’s a great opportunity for local pharmacies to educate their patients on the importance of good nutrition, healthy diets, and exercise. Springtime, March specifically, is an excellent time of year for you to start conversations with your patients about the various foods they’re eating and how they can enhance their diets to improve

article thumbnail

STAT+: An inside look at PIPEs, the financing trend that has biotech abuzz

STAT

Biotech is awash in PIPEs. The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year. Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year.

353
353
article thumbnail

AstraZeneca’s Voydeya recommended for approval in EU by CHMP

Pharmafile

AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The drug is a first-in-class oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) for the […] The post AstraZeneca’s Voydeya recommended for approval in EU by CHMP appeared first on Pharmafile.

111
111
article thumbnail

STAT+: Pfizer is about to make a big push in cancer. Will investors listen?

STAT

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution. Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen , a maker of a hot category of oncology medicines called antibody-drug conjugates.

article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

NICE recommends first licenced treatment for AL amyloidosis

European Pharmaceutical Review

Eligible individuals in England and Wales can access the first licensed treatment for amyloid light-chain (AL) amyloidosis on the NHS. The National Institute for Health and Care Excellence (NICE) recommended DARZALEX ® (daratumumab) plus VELCADE ® (bortezomib), cyclophosphamide and dexamethasone (DVCd) as an option for people newly diagnosed with the systemic form of the disease.

article thumbnail

STAT+: This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act

STAT

Jean Cui, a former Pfizer chemist whose last company was sold to Bristol Myers Squibb for $4 billion, has raised $173 million from a coalition of top biotech investors for her new company, BlossomHill Therapeutics. BlossomHill is preparing to start human clinical studies of potential medicines that could someday treat blood cancer and lung cancer. It announced Thursday that it has raised $100 million from firms including Colt Ventures, Cormorant Asset Management, and OrbiMed.

338
338
article thumbnail

The 2024 biopharma M&A landscape: An overview

pharmaphorum

It’s been a couple of months since pharma’s annual JP Morgan Chase Healthcare Conference, where the mood around pharma M&A this year was optimistic, albeit with a few caveats. On today’s podcast, host Jonah Comstock is joined by Cody Powers, principal of portfolio and business development at ZS Associates, to discuss those trends and predictions and how they’re shaking out so far.

108
108
article thumbnail

STAT+: Biotech launches with $82 million for Parkinson’s cell therapy

STAT

The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to cancer patients is materializing in the cancer world. Now, a new biotech hopes to do the same for patients with neurological conditions.  Kenai Therapeutics closed a $82 million Series A round Thursday co-led by Cure Ventures, The Column Group, and pension fund Alaska Permanent Fund Corp.

article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Lutris wins FDA orphan drug tag for EGFR inhibitor-induced rash candidate

Pharmaceutical Technology

LUT014 is being investigated in an ongoing Phase II trial as a first-line treatment for EGFR inhibitor-induced acneiform rash, for which there is no approved drug.

105
105
article thumbnail

Flu vaccine offering decent levels of protection this winter, new data show

STAT

Flu vaccine appears to be offering reasonable levels of protection this winter, with particularly strong levels in children, new data from the Centers for Disease Control and Prevention suggest. The vaccine effectiveness estimates, which showed unusually robust protection of children against influenza B viruses but more modest protection of people aged 65 and older against influenza A viruses, were presented Wednesday at a meeting of the CDC’s expert vaccine panel, the Advisory Committee

Vaccines 291
article thumbnail

Pfizer announces positive top-line data for full season two efficacy of ABRYSVO® for RSV in older adults

World Pharma News

Pfizer Inc. (NYSE: PFE) today announced top-line ABRYSVO® vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the Northern and Southern Hemispheres from the ongoing pivotal Phase 3 clinical trial (NCT05035212) RENOIR (RSV vaccine Efficacy study iNOlder adults Immunized against RSV disease).

article thumbnail

House looks to weaken Medicare negotiation

STAT

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine.  Sign up here  to receive it in your inbox on Tuesdays and Thursdays. Operation Tweak the IRA commences Two proposals to weaken Medicare’s drug price negotiation program are getting a hearing before a House Energy & Commerce subcommittee today.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

New digital iTalkBetter app significantly improves speech in stroke patients

Pharma Times

Aphasia is a language disorder caused by some form of brain damage, including stroke

133
133
article thumbnail

Listen: Legal insider trading, booming biotech stocks, & the next GLP-1

STAT

Are biotech’s dog days over? What’s a PIPE? And what can unseat Wegovy? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it’s such a good idea.

255
255
article thumbnail

APTUK: 'Enabling pharmacy technicians is about patient access'

The Pharmacist

Proposed changes to supervision and patient group directions (PGDs) will deliver increased access to care ‘for the patient’ and relieve pressures on the workforce, the vice president of the Association of Pharmacy Technicians UK (APTUK) has suggested. Nicola Stockmann addressed ‘fearmongering’ around proposed changes to supervision – which the government is accepting feedback on until […] The post APTUK: 'Enabling pharmacy technicians is about patient access' appeared first on Th

article thumbnail

Q&A: A biotech VC leader shares her next big bets

STAT

Kristina Burow has a well-trained eye. That’s true of her work at ARCH Venture Partners, one of the drug industry’s largest and most active investment firms, and also outside of work — those who know her say Burow is a deadly shot with a pistol. Burow is a managing director at ARCH, where she has been influential in building bold and well-capitalized startups.

242
242
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Seizing the moment: The life sciences industry at the threshold of change

pharmaphorum

Explore the impact of the Inflation Reduction Act (IRA) on drug prices and negotiations within the life sciences industry, as it stands on the threshold of change. Gain insights into the potential outcomes and implications of this legislation.

article thumbnail

The next act for a biotech rainmaker

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with an explanation of the latest trend in biotech financing, a big idea in oncology, and Novo Nordisk’s plans to make Wegovy obsolete.

article thumbnail

This man could be about to make MDMA legal for therapy. Are we ready for it?

The Guardian - Pharmaceutical Industry

Rick Doblin is a psychedelic pioneer – and he thinks it can help us save the world, one trauma-ending trip at a time Commanding the stage in an all-white suit and looking like a Graham Greene character or a televangelist, Rick Doblin, an unlikely guru months shy of his 70th birthday, welcomed a roaring crowd to “the psychedelic twenties”. Doblin is the founder and president of the Multidisciplinary Association for Psychedelic Studies (Maps), which sponsored last summer’s Psychedelic Science conf

101
101
article thumbnail

STAT+: Pharmalittle: We’re reading about White House eyeing PBMs, Pfizer CEO’s frustrations, and more

STAT

Top of the morning to you, and a fine one it is. Cold winds and overcast skies will not deter us from celebrating another brand new day here on the Pharmalot campus, where the official mascots are hunting for creatures and a parade of driving machines is passing near by. As for us, we are engaged in the usual ritual — brewing cups of stimulation.

211
211
article thumbnail

Rare disease spotlight: first EU-approved treatment for Friedreich’s ataxia

European Pharmaceutical Review

Last year, in agreeing to acquire Reata Pharmaceuticals for $7.3 billion , Biogen gained rights to SKYCLARYS ® (omaveloxolone), the first approved treatment for the rare disease Friedreich’s ataxia. The Committee for Medicinal Products for Human Use (CHMP) recently recommended the approval of several therapies for rare diseases, including the first oral treatment against residual haemolytic anaemia in the rare blood disorder, paroxysmal nocturnal haemoglobinuria, as well as the first therapy to

95